One year after receiving its first conditional approval for its experimental depression medicine, Cymbalta, Eli Lilly said Wednesday it received a second notice from the FDA saying the company does not need to conduct more clinical trials to get approval. However, Lilly still must resolve issues with its plant where Cymbalta will be made.

Related Summaries